Ebola diagnostics, bitopertin Phase III results and an oncology partnership.
WHO added the BioFire Global Fever Special Pathogens Panel to its Emergency Use Listing. Although the panel can detect several pathogens, the current WHO assessment covers only its Ebolavirus/Bundibugyo virus detection claims.
Why it matters: Supports outbreak diagnostic preparedness while giving procurement teams a clear boundary on the claims WHO has assessed.
Read at WHO →Disc Medicine reported that its 183-patient, placebo-controlled APOLLO trial of bitopertin met all primary and secondary endpoints in erythropoietic protoporphyria, including improved pain-free light exposure. Dizziness occurred in 50% of treated patients; the investigational medicine remains unapproved, with an FDA resubmission planned by year-end.
Why it matters: Adds late-stage evidence for a potential oral treatment for a debilitating rare disease, pending detailed data and regulatory review.
Read at Disc Medicine announcement →Roche and Hansoh announced a collaboration covering two preclinical antibody-drug conjugates and additional programmes targeting multiple cancers. Terms include $400 million upfront, $110 million on the first anniversary and potentially more than $15 billion in conditional milestones, alongside royalties.
Why it matters: Highlights continued investment in targeted oncology pipelines and cross-border development partnerships; the headline milestone value depends on future programme success.
Read at Hansoh Pharma →Editorial summaries for general information only; not medical advice. Research findings and company announcements should be read in their original context.